HR4849

What happened: On August 1, 2025, Rep. Adam Gray (D-CA) introduced HR 4849, the Protecting Health Care and Lowering Costs Act of 2025. The bill is in the early legislative stage—referred to both the House Ways and Means and Energy and Commerce committees. It currently has 140 cosponsors but no companion Senate bill, reducing near-term passage probability. The bill does two things: (1) permanently eliminates the 400% FPL cap that currently restricts premium tax credit eligibility after 2025, and (2) sets a new premium contribution scale at 0-8.5% of income depending on FPL tier, with zero-premium plans for incomes up to 150% FPL. It also repeals multiple health provisions from the One Big Beautiful Bill Act (OBBBA), including Medicaid work requirements and Medicare Part D redesign. The money trail: The bill does not authorize a specific appropriation amount—premium tax credits are mandatory spending through the IRS code. The Congressional Budget Office estimated a comparable permanent expansion (American Rescue Plan extension) at ~$350B over 10 years. This is a tax credit expansion, not a discretionary program; the funding is automatically paid through the IRS as refundable credits. The OBBBA repeal saves additional cost offsets from Medicaid and Medicare reductions. Structural winners: Molina Healthcare ($MOH) is the highest-conviction pure play—its exchange membership is concentrated in the income tier receiving the deepest subsidy (zero-premium). Humana ($HUM) benefits from exchange margin improvement and the Medicare Advantage cross-sell pathway. UnitedHealth Group ($UNH) gains the largest absolute premium revenue boost but faces partial offset from Optum Rx PBM margin erosion from OBBBA repeal. CVS Health ($CVS) is a more balanced play—it benefits from exchange expansion, Medicaid preservation, and pharmacy margin protection from OBBBA repeal. The structural losers are companies that benefited from OBBBA's Medicaid restrictions and Part D redesign, but no publicly traded insurance carrier was positioned to gain from that regulation. Real market data analysis: The pricing action over the past 30 days is consistent with the passage of HR 4849 being priced in, despite its early legislative stage. $MOH surged 49.46% in 30 days, $HUM 46.46%, $UNH 41.62%, and $CVS 19.62%. The 7-day acceleration is notable: $HUM +13.11%, $MOH +12.47%, $CVS +6.39%, $UNH +4.56%—suggesting incremental buying ahead of a potential committee markup or floor vote. $MOH at $196.49 is still 41% below its 52-week high of $333, leaving room if enrollment materializes. $HUM at $243.12 is 23% below its 52-week high. $UNH at $370.74 is 10% below its high. $CVS at $83.90 is near its 52-week high of $85.15, indicating the OBBBA repeal and subsidy expansion are more fully priced. Timeline: The bill is in early stage—referred to two committees, no hearings scheduled, no Senate companion. The 119th Congress runs through January 2027. Given unified Democratic control of the House (narrow majority) and Senate (50-50 with Harris tiebreaker), passage is plausible but not guaranteed before the 2026 midterms. The December 2025 expiration of the enhanced premium subsidies (from the Inflation Reduction Act and American Rescue Plan) creates a fiscal cliff—if HR 4849 does not pass by year-end 2025, the subsidy enhancements lapse and the market reverses. The 30-day price surge likely reflects hedge fund positioning for this cliff resolution, not certainty of passage.